Michael Thomas Heffernan
Director · 5 filings · Latest: Sep 15, 2026
Avalo Therapeutics, Inc.
Biohaven Ltd.
enGene Therapeutics Inc.
Trevi Therapeutics, Inc.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
TRVI | Michael Thomas Heffernan | Director | Sep 15, 2026 | Sale | $15.09 | 39,473 | $595.8K | 6,351 | |
TRVI | Michael Thomas Heffernan | Director | Sep 15, 2026 | Option Exercise | $3.19 | 39,473 | $126.1K | 27,403 | |
TRVI | MICHAEL HEFFERNAN | — | Sep 15, 2026 | Proposed Sale | $15.89 | 39,473 | $627.2K | — | |
COLL | Heffernan Michael Thomas | — | Jul 9, 2025 | Proposed Sale | $32.17 | 10,328 | $332.3K | — | |
COLL | Heffernan Michael Thomas | — | Jul 8, 2025 | Proposed Sale | $31.38 | 790 | $24.8K | — | |
COLL | Heffernan Michael Thomas | — | Jul 7, 2025 | Proposed Sale | $31.25 | 14,210 | $444.1K | — | |
COLL | Heffernan Michael Thomas | — | Jul 2, 2025 | Proposed Sale | $30.30 | 25,000 | $757.4K | — |